Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: Pathogenesis, prophylaxis, and antiviral therapy

Virology

Volumn 409, Issue 2, 2011, Pages 328-337

  Chen, Nanhai ^a   Bellone, Clifford J ^b   Schriewer, Jill ^b   Owens, Gelita ^c   Fredrickson, Torgny ^d   Parker, Scott ^b   Buller, R Mark L ^b  

^a GENELUX CORPORATION   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NESTLÉ RESEARCH CENTER   (Switzerland)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Ectromelia virus; IL 4.; Immunosuppression; Lethal infection; Poxvirus

Indexed keywords

CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; MONOCLONAL ANTIBODY; SMALLPOX VACCINE; TECOVIRIMAT; VACCINE; VACCINIA ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL THERAPY; ARTICLE; C57BL 6 MOUSE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; ECTROMELIA VIRUS; FEMALE; IMMUNITY; IMMUNIZATION; IMMUNOLOGICAL MEMORY; LETHALITY; LOW DRUG DOSE; MORBIDITY; MORNING DOSAGE; MOUSE; MOUSEPOX; NONHUMAN; PATHOGENESIS; POXVIRUS; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; VIRUS RECOMBINANT;

ANIMALS; ANTIVIRAL AGENTS; BENZAMIDES; CYTOSINE; ECTROMELIA VIRUS; ECTROMELIA, INFECTIOUS; FEMALE; GENE EXPRESSION REGULATION; INTERLEUKIN-4; ISOINDOLES; MICE; MICE, INBRED C57BL; PHOSPHONIC ACIDS; PROMOTER REGIONS, GENETIC; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ECTROMELIA VIRUS; MURINAE; MUS; POXVIRIDAE;

EID: 78650291480     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.10.021     Document Type: Article

References (57)

1. Andreansky S., He B., van Cott J., McGhee J., Markert J.M., Gillespie G.Y., Roizman B., Whitley R.J. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 1998, 5:121-130.
2. Andrew M.E., Coupar B.E. Biological effects of recombinant vaccinia virus-expressed interleukin 4. Cytokine 1992, 4:281-286.
3. Bembridge G.P., Lopez J.A., Cook R., Melero J.A., Taylor G. Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon. J. Virol. 1998, 72:4080-4087.
4. Benedetti S., Di Meco F., Cirenei N., Bruzzone M.G., Pollo B., Florio N., Caposio L., Colombo M.P., Cattaneo E., Finocchiaro G. IL-4 gene transfer for the treatment of experimental gliomas. Adv. Exp. Med. Biol. 1998, 451:315-321.
5. Bertholet C., Drillien R., Wittek R. One hundred base pairs of 5″ flanking sequence of a vaccinia virus late gene are sufficient to temporally regulate late transcription. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:2096-2100.
6. Bray M., Martinez M., Smee D.F., Kefauver D., Thompson E., Huggins J.W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 2000, 181:10-19.
7. Buller R.M., Owens G., Schriewer J., Melman L., Beadle J.R., Hostetler K.Y. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004, 318:474-481.
8. Buller R.M.L., Fenner F. The Mouse in Biomedical Research 2007, Elsevier, New York.
9. CDC Progressive vaccinia in a military smallpox vaccinee-United States. MMWR 2009, 58:1-4.
10. Chen N., Danila M.I., Feng Z., Buller R.M., Wang C., Han X., Lefkowitz E.J., Upton C. The genomic sequence of ectromelia virus, the causative agent of mousepox. Virology 2003, 317:165-186.
11. Chen W., Drillien R., Spehner D., Buller R.M. Restricted replication of ectromelia virus in cell culture correlates with mutations in virus-encoded host range gene. Virology 1992, 187:433-442.
12. Coupar B.E., Oke P.G., Andrew M.E. Insertion sites for recombinant vaccinia virus construction: effects on expression of a foreign protein. J. Gen. Virol. 2000, 81:431-439.
13. Davison A.J., Moss B. Structure of vaccinia virus early promoters. J. Mol. Biol. 1989, 210:749-769.
14. De Clercq E. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem. Pharmacol. 2007, 73:911-922.
15. De Clercq E., Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 2005, 4:928-940.
16. Falkner F.G., Moss B. Transient dominant selection of recombinant vaccinia viruses. J. Virol. 1990, 64:3108-3111.
17. Fernandez M., Porosnicu M., Markovic D., Barber G.N. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol. 2002, 76:895-904.
18. Fischer J.E., Johnson J.E., Kuli-Zade R.K., Johnson T.R., Aung S., Parker R.A., Graham B.S. Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus. J. Virol. 1997, 71:8672-8677.
19. Franke C.A., Hruby D.E. Association of non-viral proteins with recombinant vaccinia virus virions. Arch. Virol. 1987, 94:347-351.
20. Gessner A., Rollinghoff M. Biologic functions and signaling of the interleukin-4 receptor complexes. Immunobiology 2000, 201:285-307.
21. Ghiasi H., Cai S., Slanina S.M., Perng G.C., Nesburn A.B., Wechsler S.L. The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease. J. Infect. Dis. 1999, 179:1086-1093.
22. Ghiasi H., Osorio Y., Perng G.C., Nesburn A.B., Wechsler S.L. Recombinant herpes simplex virus type 1 expressing murine interleukin-4 is less virulent than wild-type virus in mice. J. Virol. 2001, 75:9029-9036.
23. Giampietri A., Grohmann U., Vacca C., Fioretti M.C., Puccetti P., Campanile F. Dual effect of IL-4 on resistance to systemic gram-negative infection and production of TNF-alpha. Cytokine 2000, 12:417-421.
24. Grosenbach D.W., Berhanu A., King D.S., Mosier S., Jones K.F., Jordan R.A., Bolken T.C., Hruby D.E. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc. Natl. Acad. Sci. U.S.A. 2010, 12:838-843.
25. Grunewald S.M., Kunzmann S., Schnarr B., Ezernieks J., Sebald W., Duschl A. A murine interleukin-4 antagonistic mutant protein completely inhibits interleukin-4-induced cell proliferation, differentiation, and signal transduction. J. Biol. Chem. 1997, 272:1480-1483.
26. Handley L.M., Buller R.L., Frey S.E., Bellone C.J., Parker S. The new ACAM200 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks. Expert Reviews 2009, 8:841-850.
27. Ikemoto K., Pollard R.B., Fukumoto T., Morimatsu M., Suzuki F. Small amounts of exogenous IL-4 increase the severity of encephalitis induced in mice by the intranasal infection of herpes simplex virus type 1. J. Immunol. 1995, 155:1326-1333.
28. Jackson R.J., Maguire D.J., Hinds L.A., Ramshaw I.A. Infertility in mice induced by a recombinant ectromelia virus expressing mouse zona pellucida glycoprotein 3. Biol. Reprod. 1998, 58:152-159.
29. Jackson R.J., Ramsay A.J., Christensen C.D., Beaton S., Hall D.F., Ramshaw I.A. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 2001, 75:1205-1210.
30. Kerr P.J., Perkins H.D., Inglis B., Stagg R., McLaughlin E., Collins S.V., van Leeuwen B.H. Expression of rabbit IL-4 by recombinant myxoma viruses enhances virulence and overcomes genetic resistance to myxomatosis. Virology 2004, 324:117-128.
31. Kim S.H., Evans C.H., Kim S., Oligino T., Ghivizzani S.C., Robbins P.D. Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4. Arthritis Res. 2000, 2:293-302.
32. Le Gros G., Ben Sasson S.Z., Seder R., Finkelman F.D., Paul W.E. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J. Exp. Med. 1990, 172:921-929.
33. Lukacs N.W., Addison C.L., Gauldie J., Graham F., Simpson K., Strieter R.M., Warmington K., Chensue S.W., Kunkel S.L. Transgene-induced production of IL-4 alters the development and collagen expression of T helper cell 1-type pulmonary granulomas. J. Immunol. 1997, 158:4478-4484.
34. Marchal J. Infectious ectromelia. A hitherto undescribed virus disease of mice. J. Pathol. Bacteriol 1930, 33:713-718.
35. Meko J.B., Yim J.H., Tsung K., Norton J.A. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res. 1995, 55:4765-4770.
36. Milner J.D., Orekov T., Ward J.M., Cheng L., Torres-Velez F., Junttila I., Sun G., Buller M., Morris S.C., Finkelman F.D., Paul W.E. Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation and tissue macrophage accumulation. Blood 2010.
37. Moran T.M., Isobe H., Fernandez-Sesma A., Schulman J.L. Interleukin-4 causes delayed virus clearance in influenza virus-infected mice. J. Virol. 1996, 70:5230-5235.
38. Mosmann T.R., Yokota T., Kastelein R., Zurawski S.M., Arai N., Takebe Y. Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4). J. Immunol. 1987, 138:1813-1816.
39. Moss B., Earl P.L. Expression of proteins in mammalian cells using vaccinia cirus vectors. Overview of the vaccinia virus expression system. Current Protocols in Molecular Biology 1998, Wiley.
40. Mullbacher A., Lobigs M. Creation of killer poxvirus could have been predicted. J. Virol. 2001, 75:8353-8355.
41. Neyts J., Leyssen P., Verbeken E., De Clercq E. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob. Agents Chemother. 2010, 48:2267-2273.
42. Norazmi M.N. Possible mechanism for the enhanced lethality of an interleukin-4-expressing mousepox virus. J. Med. Microbiol. 2001, 50:936.
43. Okada H., Banchereau J., Lotze M. Interleukin-4. The Cytokine Handbook 2003, Elsevier, London. A. Thomson, M. Lotze (Eds.).
44. Painter G.R., Hostetler K.Y. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol. 2004, 22:423-427.
45. Parker S., Handley L., Buller R.M. Therapeutic and prophylactic drugs to treat orthopoxvirus infections. Future Virology 2008, 3:595-612.
46. Parker S., Siddiqui A.M., Oberle C., Hembrador E., Lanier R., Painter G., Robertson A., Buller R.M. Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies. Virology 2009, 385:11-21.
47. Parker S., Touchette E., Oberle C., Almond M., Robertson A., Trost L.C., Lampert B., Painter G., Buller R.M. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res. 2008, 77:39-49.
48. Paul W.E., Ohara J. B-cell stimulatory factor-1/interleukin 4. Annu. Rev. Immunol. 1987, 5:429-459.
49. Reed L.J., Muench H.A. A simple method of estimating fifty percent endpoints. Am. J. Hygiene 1938, 27:493-497.
50. Robbins S.J., Jackson R.J., Fenner F., Beaton S., Medveczky J., Ramshaw I.A., Ramsay A.J. The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4. Antiviral Res. 2005, 66:1-7.
51. Sharma D.P., Ramsay A.J., Maguire D.J., Rolph M.S., Ramshaw I.A. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J. Virol. 1996, 70:7103-7107.
52. Smee D.F., Wong M.H., Bailey K.W., Beadle J.R., Hostetler K.Y., Sidwell R.W. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Int. J. Antimicrob. Agents 2004, 23:430-437.
53. Stanford M.M., McFadden G. The "supervirus?" Lessons from IL-4-expressing poxviruses. Trends Immunol. 2005, 26:339-345.
54. Tsung K., Yim J.H., Marti W., Buller R.M., Norton J.A. Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light. J. Virol. 1996, 70:165-171.
55. Vora S., Damon I., Fulginiti V., Weber S.G., Kahana M., Stein S.L., Gerber S.I., Garcia-Houchins S., Lederman E., Hruby D., Collins L., Scott D., Thompson K., Barson J.V., Regnery R., Hughes C., Daum R.S., Li Y., Zhao H., Smith S., Braden Z., Karem K., Olson V., Davidson W., Trindale G.B.T., Jordan R., Tien D., Marcinak J. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 2008, 15:1555-1561.
56. Wallace G.D., Buller R.M. Kinetics of ectromelia virus (mousepox) transmission and clinical response in C57BL/6j, BALB/cByj and AKR/J inbred mice. Lab Anim Sci. 1985, 35:41-46.
57. Yang G., Pevear D.C., Davies M.H., Collett M.S., Bailey T., Rippen S., Barone L., Burns C., Rhodes G., Tohan S., Huggins J.W., Baker R.O., Buller R.L., Touchette E., Waller K., Schriewer J., Neyts J., DeClercq E., Jones K., Hruby D., Jordan R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J. Virol. 2005, 79:13139-13149.